Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1957 2
1959 1
1962 1
1963 1
1964 1
1965 1
1969 1
1970 2
1971 2
1972 4
1973 4
1974 9
1975 10
1976 5
1977 3
1978 3
1979 4
1980 3
1981 1
1982 7
1983 2
1984 3
1985 4
1986 3
1987 4
1988 3
1989 6
1990 4
1992 8
1993 5
1994 3
1996 2
1997 3
1998 2
1999 1
2000 2
2001 8
2002 9
2003 11
2004 7
2005 15
2006 17
2007 21
2008 18
2009 8
2010 8
2011 7
2012 11
2013 13
2014 26
2015 22
2016 33
2017 36
2018 32
2019 45
2020 62
2021 52
2022 53
2023 58
2024 35
2025 66
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

706 results

Results by year

Filters applied: . Clear all
Page 1
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
Zlotta AR, Ballas LK, Niemierko A, Lajkosz K, Kuk C, Miranda G, Drumm M, Mari A, Thio E, Fleshner NE, Kulkarni GS, Jewett MAS, Bristow RG, Catton C, Berlin A, Sridhar SS, Schuckman A, Feldman AS, Wszolek M, Dahl DM, Lee RJ, Saylor PJ, Michaelson MD, Miyamoto DT, Zietman A, Shipley W, Chung P, Daneshmand S, Efstathiou JA. Zlotta AR, et al. Among authors: berlin a. Lancet Oncol. 2023 Jun;24(6):669-681. doi: 10.1016/S1470-2045(23)00170-5. Epub 2023 May 12. Lancet Oncol. 2023. PMID: 37187202
Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression.
Chen S, Zhu G, Yang Y, Wang F, Xiao YT, Zhang N, Bian X, Zhu Y, Yu Y, Liu F, Dong K, Mariscal J, Liu Y, Soares F, Loo Yau H, Zhang B, Chen W, Wang C, Chen D, Guo Q, Yi Z, Liu M, Fraser M, De Carvalho DD, Boutros PC, Di Vizio D, Jiang Z, van der Kwast T, Berlin A, Wu S, Wang J, He HH, Ren S. Chen S, et al. Among authors: berlin a. Nat Cell Biol. 2021 Jan;23(1):87-98. doi: 10.1038/s41556-020-00613-6. Epub 2021 Jan 8. Nat Cell Biol. 2021. PMID: 33420488
ONECUT2 is a driver of neuroendocrine prostate cancer.
Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM, Tsao MS, Wouters BG, Fazli L, Feng FY, Ellis L, van der Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang Y, He HH. Guo H, et al. Among authors: berlin a. Nat Commun. 2019 Jan 17;10(1):278. doi: 10.1038/s41467-018-08133-6. Nat Commun. 2019. PMID: 30655535 Free PMC article.
In vivo CRISPR screens identify a dual function of MEN1 in regulating tumor-microenvironment interactions.
Su P, Liu Y, Chen T, Xue Y, Zeng Y, Zhu G, Chen S, Teng M, Ci X, Guo M, He MY, Hao J, Chu V, Xu W, Wang S, Mehdipour P, Xu X, Marhon SA, Soares F, Pham NA, Wu BX, Her PH, Feng S, Alshamlan N, Khalil M, Krishnan R, Yu F, Chen C, Burrows F, Hakem R, Lupien M, Harding S, Lok BH, O'Brien C, Berlin A, De Carvalho DD, Brooks DG, Schramek D, Tsao MS, He HH. Su P, et al. Among authors: berlin a. Nat Genet. 2024 Sep;56(9):1890-1902. doi: 10.1038/s41588-024-01874-9. Epub 2024 Sep 3. Nat Genet. 2024. PMID: 39227744 Free PMC article.
The landscape of N6-methyladenosine in localized primary prostate cancer.
Xu X, Zhu H, Hugh-White R, Livingstone J, Eng S, Zeltser N, Wang Y, Pajdzik K, Chen S, Houlahan KE, Luo W, Liu S, Xu X, Sheng M, Guo WY, Arbet J, Song Y, Wang M, Zeng Y, Wang S, Zhu G, Gao T, Chen W, Ci X, Xu W, Xu K, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Têtu B, Fradet Y, Lupien M, Wei GH, Koritzinsky M, Bristow RG, Fleshner NE, Wu X, Shao Y, He C, Berlin A, van der Kwast T, Leong H, Boutros PC, He HH. Xu X, et al. Among authors: berlin a. Nat Genet. 2025 Apr;57(4):934-948. doi: 10.1038/s41588-025-02128-y. Epub 2025 Mar 24. Nat Genet. 2025. PMID: 40128621 Free PMC article.
Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial.
Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Spratt DE, et al. Among authors: berlin a. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):370-377. doi: 10.1016/j.ijrobp.2023.04.010. Epub 2023 May 2. Int J Radiat Oncol Biol Phys. 2023. PMID: 37137444 Free PMC article. Clinical Trial.
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.
Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, Decaestecker K, Kiess AP, Lumen N, Phillips R, De Bruycker A, Mishra M, Rana Z, Molitoris J, Lambert B, Delrue L, Wang H, Lowe K, Verbeke S, Van Dorpe J, Bultijnck R, Villeirs G, De Man K, Ameye F, Song DY, DeWeese T, Paller CJ, Feng FY, Wyatt A, Pienta KJ, Diehn M, Bentzen SM, Joniau S, Vanhaverbeke F, De Meerleer G, Antonarakis ES, Lotan TL, Berlin A, Siva S, Ost P, Tran PT. Deek MP, et al. Among authors: berlin a. J Clin Oncol. 2022 Oct 10;40(29):3377-3382. doi: 10.1200/JCO.22.00644. Epub 2022 Aug 24. J Clin Oncol. 2022. PMID: 36001857 Free PMC article.
Reply by Authors.
Bernardino R, Sayyid RK, Lajkosz K, Al-Daqqaq Z, Tiwari R, Cockburn J, Leão R, Metser U, Berlin A, van der Kwast T, Fleshner NE. Bernardino R, et al. Among authors: berlin a. J Urol. 2024 Apr;211(4):595. doi: 10.1097/JU.0000000000003886. Epub 2024 Feb 21. J Urol. 2024. PMID: 38382010 No abstract available.
Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials.
Dal Pra A, Ghadjar P, Ryu HM, Proudfoot JA, Hayoz S, Michalski JM, Spratt DE, Liu Y, Schär C, Berlin AM, Zwahlen DR, Simko JP, Hölscher T, Efstathiou JA, Polat B, Sandler HM, Hildebrandt G, Parliament MB, Mueller AC, Dayes IS, Plasswilm L, Correa RJM, Robertson JM, Karrison TG, Davicioni E, Hall WA, Feng FY, Pollack A, Thalmann GN, Nguyen PL, Aebersold DM, Tran PT, Zhao SG. Dal Pra A, et al. Among authors: berlin am. Ann Oncol. 2025 May;36(5):572-582. doi: 10.1016/j.annonc.2025.01.017. Epub 2025 Feb 13. Ann Oncol. 2025. PMID: 39986927 Free article. Clinical Trial.
Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation.
Teng M, Guo J, Xu X, Ci X, Mo Y, Kohen Y, Ni Z, Chen S, Guo WY, Bakht M, Ku S, Sigouros M, Luo W, Macarios CM, Xia Z, Chen M, Ul Haq S, Yang W, Berlin A, van der Kwast T, Ellis L, Zoubeidi A, Zheng G, Ming J, Wang Y, Cui H, Lok BH, Raught B, Beltran H, Qin J, He HH. Teng M, et al. Among authors: berlin a. Cancer Cell. 2025 May 12;43(5):891-904.e10. doi: 10.1016/j.ccell.2025.03.027. Epub 2025 Apr 17. Cancer Cell. 2025. PMID: 40250444 Free article.
706 results